01
What changed in pharmaceuticals regulation and policy this week?
Government decisions, new rules and policy shifts reported this week.
02
The Health Resources and Services Administration (HRSA) has selected 10 drug manufacturers and 21 drugs to participate in its revised 340B Rebate Model Pilot Program.
Read at fiercehealthcare.com ↗03
The UK Medicines and Healthcare products Regulatory Agency (MHRA) provides guidance on the New Active Substance Work Sharing Initiative (NASWSI) and the Biosimilar Work Sharing Initiative (BSWSI).
Read at gov.uk ↗04
The UK's Medicines and Healthcare products Regulatory Agency (MHRA) has joined the International Coalition of Medicines Regulatory Authorities (ICMRA) in a joint statement issued on October 1, 2026.
Read at gov.uk ↗05
The Centers for Medicare & Medicaid Services (CMS) has finalized the Global Benchmark for Efficient Drug Pricing (GLOBE) model to implement most-favored nation pricing for Medicare Part B. The program is scheduled to begin on January 1, 2027, and will run through March 31, 2032, covering approximately 25% of traditional Medicare beneficiaries. CMS Administrator Mehmet Oz stated the model aims to lower drug costs by benchmarking U.S. prices against those in economically similar countries.
Read at fiercehealthcare.com ↗06
The US Food and Drug Administration (FDA) has five user fee goal dates for novel agents scheduled for October 2026.
Read at citeline.com ↗07
The US Food and Drug Administration (FDA) is shifting its policy regarding advisory committee meetings, specifically moving away from including voting consumer representatives.
Read at citeline.com ↗08
The Council of the European Union formally adopted the EU pharma reform package on September 28, 2026.
Read at citeline.com ↗8 of 12 regulation and policy events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What funding rounds and acquisitions happened in pharmaceuticals this week?
The week’s notable investments, financing rounds, acquisitions and strategic deals.
09
The Novo Nordisk Foundation has renewed its funding commitment to the Broad Institute on September 30, 2026.
Read at broadinstitute.org ↗10
Eli Lilly CEO Dave Ricks announced at a conference in Milan that the company plans to pursue larger acquisitions to target underserved medical areas, including infectious diseases, women's health, and psychiatric conditions.
Read at thestreet.com ↗11
Merck & Co. has entered into a licensing and collaboration agreement with SciBrunch Therapeutics to develop and commercialize the preclinical oral KRAS G12D inhibitor SPR2015.
Read at genengnews.com ↗12
AstraZeneca has entered into a $2 billion deal with Summit Therapeutics to secure rights to the drug candidate ivonescimab, also referred to as Datroway.
Read at citeline.com ↗13
Milan-based biotech company Aptadir Therapeutics has raised $45 million in a seed funding round announced on September 29, 2026.
Read at tech.eu ↗14
AstraZeneca announced a $2 billion investment in Summit Therapeutics on September 28, 2026.
Read at wsj.com ↗What products launched in pharmaceuticals this week?
Notable product launches, releases and platform updates from the week.
15
A new center dedicated to advancing non-animal drug development tools has been established in Baltimore, United States.
Read at citeline.com ↗16
The Advanced Research Projects Agency for Health (ARPA-H) has launched the SURPASS program to modernize the clinical trial system in the United States.
Read at citeline.com ↗17
Google DeepMind introduced SynthID Bio on September 30, 2026, a watermarking technology for synthetic biology that embeds signatures into AI-generated protein sequences and 3D structures.
Read at deepmind.google ↗18
On September 30, 2026, the U.S. Department of Health and Human Services (HHS) announced the launch of a five-year program called SURPASS in Washington.
Read at statnews.com ↗19
The US FDA has granted a pediatric indication for Bristol Myers Squibb's drug Camzyos to treat children with obstructive hypertrophic cardiomyopathy.
Read at citeline.com ↗20
Microsoft Research has introduced Quine, an AI research system designed to create a multimodal world model of biology.
Read at microsoft.com ↗21
Cytomos has introduced AuraCyt, a predictive cell intelligence platform designed to address manufacturing bottlenecks in CAR T therapy.
Read at genengnews.com ↗22
Revolution Medicines received FDA approval in late August 2026 for Rasonque (daraxonrasib), the first RAS(ON) inhibitor for metastatic pancreatic ductal adenocarcinoma.
Read at gizmodo.com ↗8 of 10 product launches events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What financial results were reported in pharmaceuticals this week?
Earnings, guidance and other financial results reported this week.
23
Costco reported $1.849 billion in membership fee income for the fourth quarter of fiscal 2026, a 7.3% increase year-over-year.
Read at thestreet.com ↗24
Citi downgraded Moderna stock from Neutral to Sell on September 30, 2026, citing an unsustainable valuation despite the company's recent 703% share price increase.
Read at thestreet.com ↗25
Bank of America analyst Jason Gerberry raised the price target for Johnson & Johnson to $278 from $263, citing increased sales expectations for the new psoriasis drug Icotyde.
Read at thestreet.com ↗What court rulings and legal actions hit pharmaceuticals this week?
Court rulings, filings and legal actions reported this week.
26
Former U.S. Border Patrol agent Cesar Daleo was arrested in 2017 for smuggling fentanyl precursors from China to Mexico via California.
Read at foreignpolicy.com ↗27
Beam Therapeutics has filed a lawsuit against YolTech Therapeutics and Serapha Bio, alleging that a former scientist stole trade secrets related to base editing technology.
Read at pharmavoice.com ↗28
Federal authorities have charged store clerk Yahya Mohamed Mosleh and his son Islam Yahya Mosleh with possession with intent to distribute a controlled substance in Oxford, Mississippi.
Read at theguardian.com ↗What research was published in pharmaceuticals this week?
New research findings and studies published this week.
29
Researchers at the University of Wisconsin-Madison, led by Barbara Bendlin and Federico Rey, identified that the gut-produced molecule imidazole propionate (ImP) is linked to an increased risk of Alzheimer's disease.
Read at sciencedaily.com ↗30
Researchers at Northwestern University have identified a specific set of neurons in mice that drive anxiety-like behaviors following exposure to cannabinoid drugs under stressful conditions.
Read at genengnews.com ↗31
Researchers led by Jon Stefely at the Morgridge Institute for Research and the University of Wisconsin School of Medicine and Public Health have mapped the mitochondrial proteome of the pathogen Acanthamoeba castellanii.
Read at genengnews.com ↗32
A study by the SCOP-GLP1 research team, involving participants from France, the United States, Brazil, and Mexico, found a correlation between GLP-1 medication use and increased risks of hair loss and nail detachment.
Read at gizmodo.com ↗33
Eric Matthews discusses the role of Molecular Residual Disease (MRD) testing in oncology drug development.
Read at pharmexec.com ↗34
Researchers are investigating the issue of unblinding in psychedelic clinical trials, where patients often correctly identify whether they received the study drug or a placebo.
Read at pharmavoice.com ↗35
Eli Lilly presented Phase IIIb ADtouch study data for Ebglyss, targeting atopic dermatitis with hand and foot involvement.
Read at citeline.com ↗36
A 2026 survey by Pharmaceutical Strategies Group (PSG) of 250 benefits leaders shows overall satisfaction with pharmacy benefit managers (PBMs) remains stable at 7.2 out of 10.
Read at fiercehealthcare.com ↗8 of 22 research events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What incidents and outages hit pharmaceuticals this week?
Incidents, outages and safety events reported this week.
37
Inventia Healthcare Ltd., based in India, has initiated a voluntary nationwide recall of 13,567 bottles of 25-milligram chlorthalidone tablets in the United States.
Read at foxbusiness.com ↗38
Sterling Pharmaceutical Services LLC initiated a recall of over 500,000 Walgreens-branded eye-drop products on August 20, 2026, due to sterility concerns.
Read at foxbusiness.com ↗39
Kenney Blewett, a resident of Kyle, Texas, died by suicide after experiencing delays in receiving medication for his chronic obstructive pulmonary disease (COPD).
Read at kffhealthnews.org ↗40
Dozens of NHS trusts in England are experiencing shortages of essential medications including aspirin, co-codamol, and ramipril.
Read at theguardian.com ↗What partnerships were announced in pharmaceuticals this week?
Partnerships, integrations and joint projects announced this week.
41
The Medicines and Healthcare products Regulatory Agency (MHRA) and the Drug Information Association (DIA) are hosting their inaugural global summit in London on November 16-17, 2026.
Read at gov.uk ↗42
Waltz Health and Fresenius Kabi have entered a partnership to provide direct-to-employer access to three biosimilar medications in the rheumatology, dermatology, and gastroenterology categories.
Read at fiercehealthcare.com ↗43
Ginkgo Datapoints and Apheris have launched the Antibody Developability Consortium to create a large-scale standardized dataset for predicting antibody manufacturability.
Read at genengnews.com ↗3 of 5 partnerships events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.
What people moved in and out of pharmaceuticals roles this week?
Executive appointments and departures reported this week.
44
PhRMA has appointed a former congressman to succeed Steve Ubl as CEO.
Read at biopharmadive.com ↗45
Pharming CEO Fabrice Chouraqui has stepped down effective September 29, 2026, due to strategic disagreements with the board.
Read at pharmexec.com ↗2 of 3 people moves events are listed; the rest were ranked lower by importance and multi-source corroboration and are not shown.